March 2013, Highlights

Adjuvant chemotherapy should be recommended for patients with completely resected, isolated local or regional recurrence (ILRR) of breast cancer, and the argument is strongest for women with estrogen receptor (ER)-positive tumor recurrences, according to the results of the international Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer (CALOR) trial.
Read Article

Two studies presented in San Antonio reached conflicting conclusions regarding the value of dose-dense chemotherapy in patients with early breast cancer.
Read Article

Chemotherapy may not necessarily be the reason that patients with breast cancer often complain of “fuzzy thinking” and difficulty solving problems, according to research showing that cognitive changes are present in some patients at baseline, and may be related to fatigue and anxiety.
Read Article

>The molecular make-up of triple- negative breast cancer is becoming better understood, and new evidence suggests that the main biologic pathways can be targeted with drugs, according to Justin Balko, PharmD, PhD, Postdoctoral Research Fellow and Researcher, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville.
Read Article

Patients classified as low risk by the EndoPredict panel had a significantly lower rate of distant metastasis after 5 and 10 years of follow-up compared with patients who did not meet the test’s criteria for low risk, according to Peter Dubsky, MD, of the Breast Health Center, Associate Professor of Sur­gery, Medical University of Vienna, Austria.
Read Article

For the treatment of estrogen receptor (ER)-positive early breast cancer, 10 years of treatment with tamoxifen yields better outcomes than 5 years of treatment, according to an analysis from the international ATLAS study that was presented at the 2012 San Antonio Breast Cancer Symposium.
Read Article

The honor of delivering the William I. McGuire Memorial Lecture at this year’s meeting went to Gabriel N. Hortobagyi, MD, FACP, Professor of Breast Medical Oncology and Nellie B. Connally Chair in Breast Cancer at the University of Texas M.D. Anderson Cancer Center, Houston.
Read Article

Page 3 of 3